KTTA | Pasithea Therapeutics Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.87 - 3.98
52 Week Range	3.61 - 17.40
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2,060
Average Volume	13,327
Shares Outstanding	1,044,081
Market Cap	4,074,317
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-09-15

Valuation
Profitability
Growth
Health
P/E Ratio	-0.26
Forward P/E Ratio	N/A
EPS	-14.79
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	KTTA

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

KTTA's peers: ABIO, ADIL, ARTL, BCDA, BYSI, ABVC, EDSA, EQ, FBRX, INDP, NTRBW, ZIVO, MNOV, ELYM, VRAX, BWV, REVB, HILS, KPRX, KZR, KRON, QNRX, RNXT, BTTX, PXMD, KZIA, LGVN, LIXT, MNKD, MNPR, NLSP, NNVC, ONCT, ORGS, SCPH, SYRS, TTNP, VRPX, DOMH

*Chart delayed

Analyzing fundamentals for KTTA we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see KTTA Fundamentals page.

Watching at KTTA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on KTTA Technicals page.